These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 30907951)

  • 1. Understanding p53 functions through p53 antibodies.
    Sabapathy K; Lane DP
    J Mol Cell Biol; 2019 Apr; 11(4):317-329. PubMed ID: 30907951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new set of monoclonal antibodies directed to proline-rich and central regions of p53.
    Voeltzel T; Morel AP; Rostan MC; Ji J; Chiodino C; Ponchel F; Vigouroux J; Caron de Fromentel C; Soussi T; Ozturk M
    Hybrid Hybridomics; 2004 Oct; 23(5):287-92. PubMed ID: 15672606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of p53--insights into a complex process.
    Boehme KA; Blattner C
    Crit Rev Biochem Mol Biol; 2009; 44(6):367-92. PubMed ID: 19929178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new intrabody directed against the N-terminal region of human p53.
    Cohen PA; Mani JC; Lane DP
    Oncogene; 1998 Nov; 17(19):2445-56. PubMed ID: 9824155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of mutant p53 stabilization in cancer.
    Frum RA; Grossman SR
    Subcell Biochem; 2014; 85():187-97. PubMed ID: 25201195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein.
    Legros Y; Meyer A; Ory K; Soussi T
    Oncogene; 1994 Dec; 9(12):3689-94. PubMed ID: 7526318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytoplasmic side of p53's oncosuppressive activities.
    Comel A; Sorrentino G; Capaci V; Del Sal G
    FEBS Lett; 2014 Aug; 588(16):2600-9. PubMed ID: 24747877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 as an Antigen in Cancer Immunotherapy.
    Sobhani N; D'Angelo A; Wang X; Young KH; Generali D; Li Y
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
    Craig AL; Burch L; Vojtesek B; Mikutowska J; Thompson A; Hupp TR
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):133-41. PubMed ID: 10432310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNAs: p53's secret weapon in the fight against cancer?
    Dangelmaier E; Lazar SB; Lal A
    PLoS Biol; 2019 Feb; 17(2):e3000143. PubMed ID: 30759134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer cells escape p53's tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation.
    Tang J; Peng W; Feng Y; Le X; Wang K; Xiang Q; Li L; Wang Y; Xu C; Mu J; Xu K; Ji P; Tao Q; Huang A; Deng CX; Lin Y; Xiang T
    Oncogene; 2021 Sep; 40(35):5416-5426. PubMed ID: 34282274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.
    Warnock LJ; Raines SA; Milner J
    Cancer Biol Ther; 2011 Dec; 12(12):1059-68. PubMed ID: 22157150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric activation of latent p53 tetramers.
    Hupp TR; Lane DP
    Curr Biol; 1994 Oct; 4(10):865-75. PubMed ID: 7850419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity.
    Schmidt V; Nagar R; Martinez LA
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Contrived Mutant p53 Oncogene - Beyond Loss of Functions.
    Sabapathy K
    Front Oncol; 2015; 5():276. PubMed ID: 26697411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53.
    Loh SN
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32075132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putting p53 in Context.
    Kastenhuber ER; Lowe SW
    Cell; 2017 Sep; 170(6):1062-1078. PubMed ID: 28886379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor.
    Moxley AH; Reisman D
    Cell Biochem Funct; 2021 Mar; 39(2):235-247. PubMed ID: 32996618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.